NASDAQ · BNOX
Healthcare · Biotechnology
$0.25
Up+$0.01 (+4.59%)
Updated Aug 14, 2026, 12:35 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BNOX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning BNOX.
BNOX research
Company profile and research snapshot.
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 1, 2024 | HC Wainwright & Co. | Buy | — |
| Jul 18, 2024 | HC Wainwright & Co. | Buy | — |
| Jun 12, 2024 | HC Wainwright & Co. | Buy | — |
| Mar 21, 2024 | HC Wainwright & Co. | Buy | — |
| Dec 7, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 23, 2024
Neuphoria Therapeutics Inc. (NEUP) has completed the re-domiciliation of Bionomics Limited from Australia to the United States, with Neuphoria becoming the ultimate parent company. The company will issue shares, options, and a warrant related to the transaction.
GlobeNewswire Inc. · Dec 2, 2024
Bionomics, a clinical-stage biotechnology company, is reminding shareholders to vote in favor of the Scheme Implementation Agreement to re-domicile the company from Australia to the U.S. The board and an independent expert have determined that the re-domiciliation is in the best interests of shareholders.
GlobeNewswire Inc. · Oct 23, 2024
Bionomics, a clinical-stage biotechnology company, announced that it will be participating and presenting at the ThinkEquity Conference on October 30, 2024. The company's CEO, Spyros Papapetropoulos, will deliver a company presentation and management will be available for one-on-one meetings.
GlobeNewswire Inc. · May 20, 2024
ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Spyridon “Spyros” Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and presenting two posters about BNC210 as a potential treatment for social anxiety disorder and post-traumatic stress disorder (PTSD) at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place May 28 – 31 in Miami Beach, Florida. Details of the presentations are as follows:
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BNOX.
No results
No recent SID articles mention BNOX.
